ClinicalTrials.gg
Not yet recruitingNCT06337071Updated Mar 29, 2024

A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

A Phase 2 interventional study of ACYW135 Meningococcal Polysaccharide Conjugate Vaccine and ACYW135 Meningococcal Polysaccharide Vaccine in Meningococcal Meningitis, sponsored by Aimei Vacin BioPharm (Zhejiang) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 3 Months to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-29.

Sponsored by Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
3 Months to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Meningitis, Meningococcal with a site in China — 5 open to participants now, 8 under way, 5 of them phase 3. Meningitis, Meningococcal · China.

Planned enrollment
4th of 19
1,200 · median 840
Started
2024
with 3 others
Phase 2
2 of 19
1 open now
Registered
12th of 19
by date
Lead sponsor
1 of 19
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

Among the 19 studies in Meningitis, Meningococcal with a site in China, this one is the 4th largest by planned enrollment, is one of 4 that started in 2024, is one of 2 in phase 2, and was the 12th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

5 of the 19 studies in Meningitis, Meningococcal with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 3 Months to 15 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Meningitis, Meningococcal with a site in China, or all of them as a file.
02

Study summary

The purpose of this study was to explore the safety and immunogenicity of the experimental vaccine compared with the control vaccines. It is planed to enroll a total of 1,200 subjects, including 300 subjects in each of the 3-5 months old, 6-11 months old, 12-23 months old and 2-15 years old groups, who will be randomly assigned to the trial in a 1:1 ratio to study group or control group. The 3-5 month-old group will have three doses vaccination at 0, 1 and 2 month, and a booster dose at 12 months of age; the 6-11month-old and 12-23 month-old groups will each have total two doses vaccination; the 2-15 year-old group will have one dose vaccination.

Read the detailed description

The purpose of this study was to evaluate the safety and immunogenicity of the experimental vaccine(ACYW135 Meningococcal Polysaccharide Conjugate Vaccine) compared with the control vaccines(ACYW135 Meningococcal Polysaccharide Conjugate Vaccine and ACYW135 Meningococcal Polysaccharide Vaccine). It is planed to enroll a total of 1,200 subjects, including 300 subjects in each of the 3-5 months old, 6-11 months old, 12-23 months old and 2-15 years old groups, who will be randomly assigned to the trial in a 1:1 ratio to study group or control group. The 3-5 month-old group will have three doses vaccination at 0, 1 and 2 month, and a booster dose at 12 months of age; the 6-11month-old and 12-23 month-old groups will each have total two doses vaccination(at month 0, 1 or at month 0, 3); the 2-15 year-old group will have one dose vaccination. The immunogenicity and immune persistence will be evaluated by rabbit complement serum bactericidal assay.

03

Conditions studied

  • Meningococcal Meningitis
04

Who can participate

Ages eligible
3 Months to 15 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 3\~5 months old:

    1. 3\~5 months old;
    2. The subject's legal guardian voluntarily agrees to his or her child's participation in this trial and signs an form;
    3. The subject and/or the subject's legal guardian can comply with the relevant requirements of the clinical trial protocol;
    4. Have not vaccinated by any meningococcal vaccine in the past.
  • 6\~23 months old:

    1. 6\~23 months old;
    2. The subject's legal guardian voluntarily agrees to his or her child's participation in this trial and signs an informed consent form;
    3. The subject and/or the subject's legal guardian can comply with the relevant requirements of the clinical trial protocol;
    4. Have not vaccinated by any other meningococcal vaccines except meningococcal group A polysaccharide vaccine in the past. If have 1 dose vaccinated of meningococcal group A polysaccharide vaccine, it will be 3 months or more separated from the previous dose of meningococcal group A polysaccharide vaccine. If two doses of meningococcal group A polysaccharide vaccine have been vaccinated, the interval between the last dose of meningococcal group A polysaccharide vaccine should be more than 6 months or more.
  • 2\~15 years old:

    1. 2\~15 years old;
    2. The subject's legal guardian voluntarily agrees to his or her child's participation in this trial and signs an informed consent form (subjects aged 8-15 years old are also required to sign an informed consent form);
    3. The subject and/or the subject's legal guardian can comply with the relevant requirements of the clinical trial protocol; Subjects aged 2 to 6 years old have not previously been vaccinated with any meningococcal vaccine other than meningococcal polysaccharide vaccine, and the interval between the previous dose of meningococcal polysaccharide vaccine and vaccination should be more than 12 months or more; 7\~15 years old participants have not received any meningococcal vaccine in the past 3 years.

Exclusion criteria

Exclusion Criteria:

  1. The temperature before vaccination on the day of vaccination is >37.0℃;
  2. Have a history of invasive disease caused by meningococci confirmed by culture;
  3. Have a history of severe allergic reactions that require medical intervention (such as oral and throat swelling, dyspnea, hypotension or shock caused by allergies); have a history of allergies to vaccines or vaccine components (especially those allergic to diphtheria toxoid), and have concerns about vaccination History of other serious adverse reactions;
  4. Those with a clearly diagnosed history of thrombocytopenia or other coagulation disorders, which may cause for intramuscular injection;
  5. Suffer from acute disease or acute attack of chronic disease within 3 days before vaccination;
  6. Have a history of epilepsy, progressive neurological disease, Guillain-Barré syndrome, convulsions (except simple febrile convulsions) and mental illness;
  7. Known or suspected immunological dysfunction, including treatment (radiation therapy, chemotherapy, , antimetabolites, cytotoxic drugs), (HIV) infection, etc.;
  8. Known severe congenital malformations; suffering from developmental disabilities or clinically diagnosed serious chronic diseases (such as Down syndrome, diabetes, sickle cell anemia or neurological diseases);
  9. Known or suspected to have serious diseases that are judged by the researcher to affect vaccination, including respiratory diseases, digestive system diseases, endocrine system diseases, immune system diseases, cardiovascular diseases, liver and kidney diseases, malignant tumors, skin diseases, etc. ;
  10. Long-term use (continuous use for ≥14 days) of immunosuppressants or other immunomodulatory drugs (such as corticosteroids: prednisone or similar drugs) within 6 months before vaccination with the experimental vaccine, but local use (such as ointments, eye drops, inhalants, or nasal sprays), topical administration should not exceed the dosage recommended in the label;
  11. Have received blood products including gamma globulin or immune globulin treatment within 3 months before vaccination (\<3 months);
  12. Asplenia or functional asplenia, asplenia or splenectomy caused by any condition;
  13. Have been vaccinated with within 14 days (including 14 days) before vaccination, and have been vaccinated with other subunits, inactivated vaccines or recombinant protein vaccines other than live attenuated vaccines within 7 days (including 7 days);
  14. Currently participating in or planning to participate in other drug clinical trials during the entire trial period after receiving the experimental vaccine;
  15. Any situation that the researcher believes may affect the evaluation of the trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Experimental Group 2~15 years

    2\~15 years old participants who vaccinated by experimental vaccine

    Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

  • Active comparator
    Control Group 2~15 years

    2\~15 years old participants who vaccinated by control vaccine 2

    Biological: ACYW135 Meningococcal Polysaccharide Vaccine

  • Experimental
    Experimental Group 6~23 months(0,1)

    6\~23 months old participants who vaccinated by experimental vaccine at month 0 and 1

    Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

  • Active comparator
    Control Group 6~23 months(0,1)

    6\~23 months old participants who vaccinated by control vaccine 1 at month 0 and 1

    Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

  • Experimental
    Experimental Group 6~23 months(0,3)

    6\~23 months old participants who vaccinated by experimental vaccine at month 0 and 3

    Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

  • Active comparator
    Control Group 6~23 months(0,3)

    6\~23 months old participants who vaccinated by control vaccine 1 at month 0 and 3

    Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

  • Experimental
    Experimental Group 3~5 months

    3\~5 months old participants who vaccinated by experimental vaccine at month 0, 1, 2 for primary vaccination, and vaccinated by experimental vaccine at 12-month old for booster vaccination

    Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

  • Active comparator
    Control Group 3~5 months

    3\~5 months old participants who vaccinated by control vaccine 1 at month 0, 1, 2 for primary vaccination, and vaccinated by control vaccine at 12-month old for booster vaccination

    Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

Interventions

  • BiologicalACYW135 Meningococcal Polysaccharide Conjugate Vaccine

    ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.

  • BiologicalACYW135 Meningococcal Polysaccharide Vaccine

    ACYW135 Meningococcal Polysaccharide Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135.

06

What researchers measure

Primary outcomes

  1. Immunogenicity 1

    To evaluate the positive conversion rate and geometric mean titer (GMT) of meningococcal serum bactericidal activity (rSBA) antibodies for meningococcal groups A, C, Y, and W135 at 30 days in 3\~5 months old participants after primary vaccination

    Time frame: 30 days after primary vaccination

  2. Immunogenicity 2

    To evaluate the positive conversion rate and geometric mean titer (GMT) of meningococcal serum bactericidal activity (rSBA) antibodies for meningococcal groups A, C, Y, and W135 at 30 days in 6\~23 months old participants after two doses vaccination

    Time frame: 30 days after two doses vaccination

  3. Immunogenicity 3

    To evaluate the positive conversion rate and geometric mean titer (GMT) of meningococcal serum bactericidal activity (rSBA) antibodies for meningococcal groups A, C, Y, and W135 at 30 days in 2\~15 years old participants after one dose vaccination

    Time frame: 30 days after one dose vaccination

  4. Safety 1

    The incidence of adverse events (AEs)/vaccination-related AEs on days 0 to 30 after each dose of immunization for subjects in each age group

    Time frame: 30 days after each dose vaccination

Secondary outcomes

  1. Immunogenicity 4

    To evaluate the positive rate of serum bactericidal activity (rSBA) antibodies against meningococcal groups A, C, Y and W135 (ratio of antibody titers ≥1:8), ratio of antibody titer ≥1:128, geometric mean growth factor (GMFI) in 3\~5 months old participants after primary vaccination

    Time frame: 30 days after booster vaccination

  2. Immunogenicity 5

    To evaluate the serum bactericidal activity (rSBA) antibody GMT, positivity rate and rate of antibody titer ≥1:128 subjects in 3\~5 months old participants before booster vaccination

    Time frame: Before booster vaccination

  3. Immunogenicity 6

    To evaluate the serum bactericidal activity (rSBA) antibody positive conversion rate, GMT, GMFI, positivity rate, and rate of antibody titer≥ 1:128 ratio in 3\~5 months old participants after booster vaccination

    Time frame: 30 days after booster vaccination

  4. Immunogenicity 7

    To evaluate the positive rate of serum bactericidal activity (rSBA) antibodies against meningococcal groups A, C, Y and W135 (ratio of antibody titers ≥1:8), ratio of antibody titer ≥1:128, geometric mean growth factor (GMFI) in 6\~23 months old participants after two doses vaccination

    Time frame: 30 days after booster vaccination

  5. Immunogenicity 8

    To evaluate the positive rate of serum bactericidal activity (rSBA) antibodies against meningococcal groups A, C, Y and W135 (ratio of antibody titers ≥1:8) and ratio of antibody titer ≥1:128 in 6\~23 months old participants after vaccination

    Time frame: 30 days after vaccination

  6. Immune persistence 1

    To evaluate the serum bactericidal activity (rSBA) antibody positivity rate, rate of antibody titer ≥1:128 and GMT in 3\~5 months old participants after booster vaccination

    Time frame: 6 months after booster vaccination

  7. Immune persistence 2

    To evaluate the serum bactericidal activity (rSBA) antibody positivity rate, rate of antibody titer ≥1:128 and GMT in 6\~23 months old participants after two doses vaccination

    Time frame: 6 months, 12 months

  8. Safety 2

    AEs/vaccination-related AEs are divided into doses, severity, vaccination site and non-vaccination site, and system organs (SOC) classification and incidence of each preferred term (PT) symptom after each dose vaccination

    Time frame: 30 days after each dose vaccination

  9. Safety 3

    The occurrence of serious adverse events (SAE) in each group of subjects aged 3 to 5 months from the first dose vaccination to 6 months after primary vaccination and within 30 days after booster vaccination

    Time frame: 6 months after primary vaccination and 30 days after booster vaccination

  10. Safety 4

    The occurrence of serious adverse events (SAE) in each group of subjects aged 2\~15 years and 6\~23 months from the first dose vaccination to 6 months after all doses vaccination

    Time frame: 6 months after all doses vaccination

07

Study locations

1 site
  • Yunnan Center For Disease Control and Prevention
    Kunming, Yunnan 650022, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2024; primary completion for Jun 2024, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 29, 2024
StartEst.
Mar 20, 2024
Primary completionEst.
Jun 2024
CompletionEst.
Jun 2025
Last update
Mar 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06337071
Lead sponsor
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
Responsible party
Sponsor
First posted
Mar 29, 2024
Start date
Mar 20, 2024 (estimated)
Primary completion
Jun 2024 (estimated)
Completion
Jun 2025 (estimated)
Last update
Mar 29, 2024

Study contacts

ZHENG Yan
Contact
yaqueer_zy@163.com
+8687163627796
ZHENG Yan
principal investigator · YUNNAN CENTER FOR DISEASE CONROL AND PREVENTION

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion